Metastatic Malignant Melanoma Clinical Trial
Official title:
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
The purpose of this study is to determine the antitumor activity and safety profile of IMC-1121B (ramucirumab) when used alone or in combination with dacarbazine in participants with metastatic melanoma who have not received prior chemotherapy for this disease. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02617849 -
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
|
Phase 2 | |
| Terminated |
NCT00304200 -
Temodar and Sutent as Therapy for Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01654692 -
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT02350972 -
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
|
Phase 1 | |
| Terminated |
NCT01705392 -
Bevacizumab vs Dacarbazine in Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00625768 -
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
|
Phase 1 | |
| Terminated |
NCT00961844 -
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00462423 -
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
|
Phase 2 |